Stockscreener 앱 받기
7.42
1.64%
0.12
시간 외 거래:
7.47
0.05
+0.67%
전일 마감가:
$7.30
열려 있는:
$7.21
하루 거래량:
1.94M
Relative Volume:
1.08
시가총액:
$870.31M
수익:
-
순이익/손실:
$-29.07M
주가수익비율:
-25.59
EPS:
-0.29
순현금흐름:
$-31.85M
1주 성능:
+1.23%
1개월 성능:
+26.73%
6개월 성능:
+75.00%
1년 성능:
+165.00%
1일 변동 폭
$6.55
$7.47
1주일 범위
$6.55
$7.52
52주 변동 폭
$2.36
$8.11
트레비 테라퓨틱스 Stock (TRVI) Company Profile
명칭
Trevi Therapeutics Inc
전화
203-304-2499
주소
195 CHURCH STREET, NEW HAVEN, CT
TRVI을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.42 | 885.16M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
트레비 테라퓨틱스 Stock (TRVI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-03-10 | 재확인 | Needham | Buy |
| 2025-03-10 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-09 | 재개 | Leerink Partners | Outperform |
| 2024-08-30 | 개시 | H.C. Wainwright | Buy |
| 2024-08-30 | 개시 | Raymond James | Outperform |
| 2024-06-13 | 개시 | Rodman & Renshaw | Buy |
| 2023-04-12 | 개시 | B. Riley Securities | Buy |
| 2022-11-22 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | BMO Capital Markets | Outperform |
| 2019-06-03 | 개시 | Needham | Buy |
| 2019-06-03 | 개시 | SVB Leerink | Outperform |
| 2019-06-03 | 개시 | Stifel | Buy |
모두보기
트레비 테라퓨틱스 주식(TRVI)의 최신 뉴스
Trevi Therapeutics' Path to Sustainable Growth and Value Creation - AInvest
Trevi Therapeutics (NASDAQ:TRVI) Is In A Good Position To Deliver On Growth Plans - Yahoo Finance
Trevi Therapeutics (TRVI): A High-Potential Biotech Play in Chronic Cough with a Clear Path to Phase 3 and FDA Alignment - AInvest
Needham & Company LLC Has Lowered Expectations for Trevi Therapeutics (NASDAQ:TRVI) Stock Price - MarketBeat
Trevi Therapeutics outlines $204M cash runway into 2029 as Phase III programs advance following positive CORAL data - MSN
Unlocking Long-Term Value: Trevi Therapeutics' Strategic Capital Efficiency and Robust Clinical Data Drive Phase III Momentum - AInvest
Transcript : Trevi Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Promising Phase 2b Results and Strong Financial Position Drive Buy Rating for Trevi Therapeutics - TipRanks
Earnings call transcript: Trevi Therapeutics Q2 2025 shows slight EPS beat - Investing.com Australia
Trevi Therapeutics Gears Up For Next Phase After Positive Results - Finimize
Trevi Therapeutics Inc (TRVI) Q2 2025 Earnings Call Highlights: Strategic Advances and Financial Strength - GuruFocus
Trevi Therapeutics Reports Positive Trial Results and Financial Stability - TipRanks
Trevi Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Trevi Therapeutics Q2 EPS beats estimates - MarketScreener
Trevi Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates - PR Newswire
Trevi Therapeutics TRVI Q2 2025 Earnings Preview Upside Potential with Positive Share Dynamics - AInvest
Trevi Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 7, 2025 - 富途牛牛
Is Trevi Therapeutics Inc. stock overvalued or undervaluedMassive profits - Jammu Links News
Should I hold or sell Trevi Therapeutics Inc. stock in 2025Free Investment Timing Strategies - Jammu Links News
What is the risk reward ratio of investing in Trevi Therapeutics Inc. stockUnlock daily stock market insights for success - Jammu Links News
What makes Trevi Therapeutics Inc. stock price move sharplyFree Market Dynamics Reports - Jammu Links News
Published on: 2025-08-03 17:59:19 - Jammu Links News
When is Trevi Therapeutics Inc. stock expected to show significant growthFree Buy/Sell Signal Notifications - Jammu Links News
How strong is Trevi Therapeutics Inc. company’s balance sheetUnlock powerful trading alerts for success - Jammu Links News
What analysts say about Trevi Therapeutics Inc. stockUnlock rapid growth potential in your portfolio - Jammu Links News
Why is Trevi Therapeutics Inc. stock attracting strong analyst attentionExceptional market performance - Jammu Links News
What institutional investors are buying Trevi Therapeutics Inc. stockMarket Forecast Recommendation With Low Risk - Jammu Links News
Trevi Therapeutics to Report Second Quarter 2025 Financial Resul - GuruFocus
Trevi Therapeutics Q2 Earnings: Key Updates on Chronic Cough Drug Trials Coming August 7 - Stock Titan
Is it the right time to buy Trevi Therapeutics Inc. stockEntry Signal Growth Plan For Every Investor - Jammu Links News
Trend analysis for Trevi Therapeutics Inc. this weekLow Risk Buy Zone Opportunity Watch Ongoing - metal.it
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionScalable Strategy with Chart Confirmation - Newser
Has Trevi Therapeutics Inc. formed a bullish divergenceFundamental + Technical Combined Watchlist - Newser
Predicting Trevi Therapeutics Inc. trend using moving averagesRisk Balanced Picks for Safer Trading - Newser
Bullish Candlestick Pattern Forms in Trevi Therapeutics Inc.Weekly Stock Opportunity Radar Scanner Activated - metal.it
Developing predictive dashboards with Trevi Therapeutics Inc. dataDaily Market Entry Strategy with Tools - Newser
Trevi Therapeutics Inc. Earnings Report Breakdown: What Investors Should KnowWeekly Hot Stocks Based on Volume Flow - Newser
Trevi Therapeutics Inc.’s Beta Climbs After Market VolatilityAI Screening for Swing Trade Picks Finds Momentum - metal.it
Why did Trevi Therapeutics' operating expenses surge in Q3 2024? - AInvest
Trevi Therapeutics to Participate in Upcoming August Conferences - PR Newswire
Trevi Therapeutics To Participate In Upcoming August Conferences - Barchart.com
Trevi Therapeutics Inc. Shows Early Signs of Technical StrengthFast Exit and Entry Strategy Guide Offered - metal.it
Trevi Therapeutics Inc. Stock Support and Resistance Levels You Should Know Stable Profit Zone and Loss Control Analysis - beatles.ru
Is Trevi Therapeutics Inc. a growth stock or a value stockBuild a diversified portfolio for steady growth - Jammu Links News
Brokerages Set Trevi Therapeutics, Inc. (NASDAQ:TRVI) Target Price at $20.88 - Defense World
Trevi Therapeutics Inc. Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
Should I buy Trevi Therapeutics Inc. stock before earningsFree Capital Allocation Plans - jammulinksnews.com
What drives Trevi Therapeutics Inc. stock priceUnprecedented profit potential - PrintWeekIndia
Is Trevi Therapeutics Inc. a good long term investmentHigh-profit trading signals - Autocar Professional
트레비 테라퓨틱스 (TRVI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):